As of November 6, 2026, Johnson & Johnson (JNJ) trades at $276.22. Equity Rank's blended estimate across 9 valuation models with sufficient data is $244.26 — a model fair value differential of 11.6% below the current price under these model assumptions. Model-derived estimate, informational only — not investment advice.
Source: Equity Rank — JNJ fair value (data as of 2026-11-06). The full page adds the per-method breakdown and the model’s scenario range (with an Equity Rank account).
Reported EPS came in above the analyst estimate in 7 of the last 8 reports. The median share-price change across a report, in either direction, was 1.4%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Oct 13, 2026 | $2.53 | $2.59 | +2.4% | -5.7% |
| Jul 15, 2026 | $2.84 | $2.90 | +2.1% | -2.7% |
| Apr 14, 2026 | $2.68 | $2.70 | +0.7% | +0.9% |
| Jan 21, 2026 | $2.46 | $2.46 | 0.0% | -0.1% |
| Oct 14, 2025 | $2.76 | $2.80 | +1.4% | -0.0% |
| Jul 16, 2025 | $2.68 | $2.77 | +3.4% | +6.2% |
| Apr 15, 2025 | $2.58 | $2.77 | +7.4% | -0.5% |
| Jan 22, 2025 | $2.01 | $2.04 | +1.5% | -1.9% |
Equity Rank computed model fair value for JNJ from 9 independent valuation methods with sufficient data. 2 place fair value above the current price of $276.22, and 7 place it below. The model-blended estimate lands at $244.26 — a model fair value differential of 11.6% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores JNJ at 69.2/100 (B, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +4.7% per year and gross margin has moved -1.4 pp. Its SAVE composite score has moved -4.9 over the past 30 days.
Equity Rank's intrinsic value estimate for Johnson & Johnson (JNJ) — the model fair value — is $244.26 as of November 6, 2026, blended from 9 valuation methods with sufficient data. An intrinsic value estimate is what the models compute a share to be worth under stated assumptions; it is not a price target, not a prediction of where the stock will trade, and not investment advice.
Equity Rank calculates fair value for JNJ by blending 19 valuation methods (8–15 run per security depending on data availability), including DCF, Graham Number, Price-to-Free-Cash-Flow, EPV, Three-Stage DCF, DDM, Residual Income, and Justified Price-to-Book. Each model is weighted by historical sector accuracy and updated regularly. Informational only — not investment advice.
Johnson & Johnson (JNJ) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Johnson & Johnson (JNJ) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
More on JNJ: Is JNJ overvalued? · If you had invested $1,000 in JNJ · JNJ dividend income
Side-by-side valuation: JNJ vs PFE · JNJ vs ABBV · LLY vs JNJ · JNJ vs MRK · JNJ vs NVS · JNJ vs AZN
ETFs holding JNJ (share of fund): XLV (9.7%) · MTUM (3.0%) · DIA (2.9%) · VIG (2.8%) · VYM (2.7%) · VTV (2.4%)
All General Drug Manufacturers stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/JNJ. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of November 6, 2026 and are recomputed after every U.S. market close.